Indapamid coated tablets 2.5 mg. №30

Description

Indapamid Composition
active substance: indapamide;

1 tablet contains 2.5 mg indapamide;

excipients: corn starch; lactose monohydrate; povidone; magnesium stearate; sodium lauryl sulfate; coverage: hypromelose 2910, 5 cps; PEG 6000; titanium dioxide (E 171).

Indapamid Dosage form.

Film-coated tablets.

Basic physical and chemical properties: round tablets with a biconvex surface, white coated. Two layers are visible on the fault.

Indapamid Pharmacotherapeutic group.

Non-thiazide diuretics with moderate diuretic activity. ATX code C03B A11.

Pharmacological properties

Pharmacodynamics.

Indapamide is a sulfonamide diuretic that is pharmacologically related to thiazide diuretics. Indapamide inhibits sodium reabsorption in the cortical segment of the kidney.

This increases the excretion of sodium and chloride in the urine and, to a lesser extent, the excretion of potassium and magnesium, thus increasing urine output. The antihypertensive effect of indapamide is manifested at doses that produce a slight diuretic effect. Moreover, its antihypertensive effect persists even in hypertensive hemodialysis patients.

Indapamide acts at the vascular level by:

a decrease in the contractility of vascular smooth muscles, which is associated with changes in the transmembrane exchange of ions (mainly calcium);
stimulation of the synthesis of prostaglandin PGE2 and prostacyclin PGI2 (vasodilator and inhibitor of platelet aggregation).
Indapamide reduces left ventricular hypertrophy.

Moreover, as shown by studies of different duration (short, medium and long) with the participation of patients with arterial hypertension, indapamide:

does not affect the metabolism of lipids: triglycerides, low density lipoprotein cholesterol and high density lipoprotein cholesterol;
does not affect the metabolism of carbohydrates, even in patients with arterial hypertension and diabetes mellitus.
When the recommended dose is exceeded, the therapeutic effect of thiazides and thiazine-like diuretics does not increase, while the number of undesirable effects increases. If the treatment is not effective enough, it is not recommended to increase the dose.

Pharmacokinetics.

Absorption.

The bioavailability of indapamide is high – 93%. The maximum concentration in blood plasma is reached within 1-2 hours after taking a dose of 2.5 mg.

Distribution.

Plasma protein binding is above 75%. The half-life is 14-24 hours (average 18 hours). With regular administration, the level of a stable concentration of indapamide in the blood plasma (plateau) increases compared to the concentration of indapamide in the blood plasma after taking a single dose. This level of concentration in blood plasma remains stable for a long time without the occurrence of cumulation.

Excretion.

Renal clearance is 60-80% of the total clearance. Indapamide is excreted mainly in the form of metabolites, part of the drug that is excreted by the kidneys unchanged is 5%. In patients with renal insufficiency, pharmacokinetic parameters do not change.

Clinical characteristics.

Indications
Essential hypertension.

Contraindications
Hypersensitivity to indapamide, other sulfonamides, or to any other components of the drug. Severe renal failure, hepatic encephalopathy or severe liver dysfunction, hypokalemia.